Cam Gallagher, MBA

Mr. Gallagher is a serial biotechnology entrepreneur with over 33 years of experience in the biotechnology and pharmaceutical industry as an executive, company founder, investor and board member. He is currently President & CEO of Alessa Therapeutics. Alessa is a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early treatment of prostate cancer. He previously served as Co-Founder, President & Board Member of Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. He also served as Chief Business Officer of Retrosense Therapeutics, a clinical stage gene therapy company focused on inherited retinal disorders, through their acquisition by Allergan.

Cam currently serves on the board of directors for Opus Genetics (Nasdaq: IRD), SelectION, Immusoft and UC San Diego Moores Cancer Center. His previous board roles include VelosBio (acquired by Merck for $2.8B), Retrosense Therapeutics (acquired by Allergan for up to $580M) and Zentalis Pharma (Nasdaq: ZNTL). Cam received his B.B.A. from Ohio University and his M.B.A. from the University of San Diego focusing on finance and marketing.